Category: Sanofi
-
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies WASHINGTON — President Trump often brags that the “most-favored nation” deals he struck with drugmakers have set the country on a new path to no longer paying more than its fair share for prescription drug costs. But many details of the…
-
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. It’s Day 3 of JPM and all of us — Matt, Elaine, Adam, and Allison — are…
-
An AI experiment at the FDA & Novo trailing in the obesity drug race
An AI experiment at the FDA & Novo trailing in the obesity drug race On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech. The FDA has rolled out an internal AI tool called…
-
RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived
RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived A new report from the Centers for Disease Control and Prevention shows there was a substantial drop in hospitalizations for respiratory syncytial virus this winter among very young children, who are at the highest risk of becoming severely ill if they contract…